论文部分内容阅读
美国Introgen Therapeutics公司及其在瑞士的子司Gendux Molecular已经向欧盟递交了其研发的p53基因产品Advexin的上市申请,希望该产品能被批准用于李-弗若曼癌症综合征(Li-Fraumeni syn-drome carcers)。Advexin是一种含有正常p53肿瘤抑制基因的、非复制的5型腺病毒介导物(ade
Gendux Molecular, a division of Introgen Therapeutics in the United States and its subsidiary in Switzerland, has submitted a listing application of its gene p53 product Advexin to the European Union in the hope that it will be approved for Li-Fraumeni syn -drome carcers). Advexin is a non-replicating adenovirus-type 5 adenovirus vector containing the normal p53 tumor suppressor